70 participants
Comparing the Effectiveness of the Immunotherapy Agents Rituximab or Mosunetuzumab in Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma, NORM Trial
- Study Type:
- INTERVENTIONAL
- Last Updated:
- 2026-08-05
- Start Date:
- 2024-01-23
- Completion:
- 2026-10-31
Conditions
- Nodular Lymphocyte Predominant B-Cell Lymphoma
- Recurrent Nodular Lymphocyte Predominant B-Cell Lymphoma
- Refractory Nodular Lymphocyte Predominant B-Cell Lymphoma
Interventions
- PROCEDURE
- OTHER
- BIOLOGICAL
No Results Yet